Feasibility of short-term temporary discontinuation of serotonin reuptake inhibitors in patients planned for hip or knee arthroplasty

Conditions

Hip and knee osteoarthritis

Brief summary

The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who are able to discontinue SSRI/SNRI therapy perioperatively.

Detailed description

The proportions of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who opt out of the tapering of SSRI/SNRI therapy due to discontinuation syndrome, relapse of depression, relapse of anxiety or other reasons., The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who are not able to discontinue SSRI/SNRI therapy completely, but able to reduce their doses., Discontinuation-Emergent Signs and Symptoms (DESS), Major Depression Inventory (MDI) and Symptom Checklist 92 (SCL-92) score at baseline, after 2 weeks, the day before surgery (after 5 weeks) and 2 months after surgery., The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who uses SSRIs/SNRIs 2 months after surgery., The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy able to discontinue SSRI/SNRI therapy perioperatively who uses SSRIs/SNRIs 2 months after surgery.

Related papers

No related papers found yet.

Interventions

DRUGDULOXETINE

DRUGSERTRALINE

DRUGPAROXETINE

DRUGESCITALOPRAM

DRUGCITALOPRAM

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who are able to discontinue SSRI/SNRI therapy perioperatively.	—

Secondary

Measure	Time frame
The proportions of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who opt out of the tapering of SSRI/SNRI therapy due to discontinuation syndrome, relapse of depression, relapse of anxiety or other reasons., The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who are not able to discontinue SSRI/SNRI therapy completely, but able to reduce their doses., Discontinuation-Emergent Signs and Symptoms (DESS), Major Depression Inventory (MDI) and Symptom Checklist 92 (SCL-92) score at baseline, after 2 weeks, the day before surgery (after 5 weeks) and 2 months after surgery., The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who uses SSRIs/SNRIs 2 months after surgery., The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy able to discontinue SSRI/SNRI therapy perioperatively who uses SSRIs/SNRIs 2 months after surgery.	—

Measure

Time frame

The proportions of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who opt out of the tapering of SSRI/SNRI therapy due to discontinuation syndrome, relapse of depression, relapse of anxiety or other reasons., The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who are not able to discontinue SSRI/SNRI therapy completely, but able to reduce their doses., Discontinuation-Emergent Signs and Symptoms (DESS), Major Depression Inventory (MDI) and Symptom Checklist 92 (SCL-92) score at baseline, after 2 weeks, the day before surgery (after 5 weeks) and 2 months after surgery., The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy, who uses SSRIs/SNRIs 2 months after surgery., The proportion of patients planned for THA/TKA/UKA in SSRI/SNRI therapy able to discontinue SSRI/SNRI therapy perioperatively who uses SSRIs/SNRIs 2 months after surgery.

—

Countries

Denmark

Outcome results

None listed